AbCellera Biologics Inc.
ABCL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $29 | $38 | $485 | $375 |
| % Growth | -24.2% | -92.2% | 29.4% | – |
| Cost of Goods Sold | $0 | $0 | $66 | $46 |
| Gross Profit | $29 | $38 | $419 | $330 |
| % Margin | 100% | 100% | 86.3% | 87.9% |
| R&D Expenses | $167 | $176 | $108 | $62 |
| G&A Expenses | $73 | $61 | $55 | $42 |
| SG&A Expenses | $85 | $75 | $67 | $49 |
| Sales & Mktg Exp. | $13 | $14 | $11 | $7 |
| Other Operating Expenses | $91 | $24 | $28 | $14 |
| Operating Expenses | $344 | $275 | $202 | $125 |
| Operating Income | -$315 | -$237 | $217 | $204 |
| % Margin | -1,091.7% | -623.8% | 44.6% | 54.5% |
| Other Income/Exp. Net | $114 | $63 | $23 | $15 |
| Pre-Tax Income | -$200 | -$174 | $239 | $219 |
| Tax Expense | -$38 | -$28 | $81 | $66 |
| Net Income | -$163 | -$146 | $159 | $153 |
| % Margin | -564.8% | -385% | 32.7% | 40.9% |
| EPS | -0.55 | -0.51 | 0.56 | 0.56 |
| % Growth | -7.8% | -191.1% | 0% | – |
| EPS Diluted | -0.55 | -0.51 | 0.5 | 0.48 |
| Weighted Avg Shares Out | 294 | 289 | 285 | 276 |
| Weighted Avg Shares Out Dil | 294 | 289 | 315 | 318 |
| Supplemental Information | – | – | – | – |
| Interest Income | $38 | $42 | $16 | $3 |
| Interest Expense | $0 | $0 | $4 | $5 |
| Depreciation & Amortization | $97 | $31 | $33 | $17 |
| EBITDA | -$204 | -$192 | $260 | $239 |
| % Margin | -708% | -505.3% | 53.6% | 63.7% |